Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial

Table 5 Repeated-measures analysis of variance assessments at baseline and after six and twelve weeks of treatment

	Group effect			Time effect			Interaction
	F	df	p	F	df	p	F	df	p
PANSS positive	0.433	1,33	0.51	47.748	1.9,62.2	<0.0001	18.72	1.6,52.4	<0.0001
PANSS negative	1.575	1,33	0.21	186.771	1.1,35.7	<0.0001	5.20	1.1,35.7	<0.0001
PANSS general psychopathology	16.186	1,33	<0.0001	55.972	1.9,63.7	<0.0001	1.7	1.1,36.3	0.19
PANSS depression/anxiety	83.049	1,33	<0.0001	115.78	1.38,45.7	<0.0001	106.49	1.14,37.8	<0.0001
PANSS total	1.006	1,33	0.32	186.397	1.4,47.5	<0.0001	7.51	1.4,45.6	0.001
GAF	0.000	1,33	0.993	522.74	1.35,44.5	<0.0001	1.66	1.23,40.6	0.197
SAS	497.46	1,33	<0.0001	391.60	1.9,62.6	<0.0001	320.43	1.9,63.3	<0.0001

df = degrees of freedom; F = F-test; GAF = Global Assessment of Functioning; p = p-value; PANSS = Positive and Negative symptoms Scale; SAS = Simpson Angus scale.